🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Symptoms of nOH can greatly impact one’s ability to conduct routine daily activities—especially those requiring standing or walking. Consider joining us as we take another step toward the goal of symptom relief in people with nOH & MSA. For more info visit cypress-study.com

Theravance Biopharma is currently recruiting for the Phase 3 CYPRESS #clinicaltrial evaluating the efficacy & safety of a once-daily investigational drug with the goal of symptom relief in people with nOH & #multiplesystematrophy. Learn more on qualifying: cypress-study.com

Theravance continues to enroll for our Phase 3 CYPRESS study. Consider joining us as we take another critical step toward the goal of managing symptoms of nOH for people with MSA. For more information, visit our study website at cypress-study.com

Living with a rare disease—or caring for someone who does—often means facing unique challenges, from finding a diagnosis to navigating daily life. On #RareDiseaseDay, we stand together to recognize the patients and caregivers who show us the true meaning of strength every day.

MSA may be rare, but the impact is far-reaching. This #MSAAwarenessMonth, we honor the incredible strength of those living with Multiple System Atrophy and the caregivers who stand beside them. You inspire us every day.

#PRWeek2025 calls attention to the role of pulmonary rehabilitation in enhancing the quality of life of individuals with lung disease. Show your support by participating in this year's celebration, taking place March 9-15: aacvpr.org/Cardiac-Pulmon…

Theravance is actively recruiting for the Phase 3 CYPRESS clinical trial evaluating the efficacy and safety of a once-daily investigational drug with the goal of symptom relief in people with nOH and MSA. Contact us at [email protected] or call +1-855-633-8479 for more info.

Do you, or someone you know, have an MSA diagnosis and are experiencing symptoms of nOH? Watch as our very own Dr. Norcliffe-Kaufmann explains the symptoms of those suffering from the symptoms of nOH. Visit cypress-study.com to learn more about the study.

Theravance Biopharma is attending the @AANMember annual meeting in San Diego and presenting two new analyses of the initial Phase 3 program of ampreloxetine (Studies 0169 and 0170) on April 7. We’re excited to present these results and hope to see you there! #AANAM

New ampreloxetine analyses of the previous Phase 3 Program (Studies 169 & 170) will be presented today in back-to-back oral presentations at the American Academy of Neurology Annual Meeting in San Diego! 11:15am PT and 11:27am PT in the S9-Autonomic Disorders Scientific Platform Session. #AANAM

Theravance continues to enroll in our Phase 3 CYPRESS clinical trial. Symptoms of nOH can impact routine daily activities - especially those requiring standing or walking - for people with MSA. For more info visit our study website cypress-study.com

Theravance is excited to sponsor and attend the MSA Symposium! This exciting event will showcase the latest breakthroughs in clinical and basic science research on Multiple System Atrophy (MSA) and atypical parkinsonism. MSA Trust UCL Queen Square Institute of Neurology More info: multiplesystematrophytrust.regfox.com/msa-research-s…

Theravance is attending the International MSA Congress Presented by Mission MSA in Boston and presenting analyses of the initial Phase 3 program of ampreloxetine (Studies 0169 and 0170) on May 9-10. We’re excited to present these analyses and hope to see you there! #MSA2025

Thank you to all who made the MSA Symposium 2025 such an incredible experience. We appreciated the opportunity to connect with attendees and participate in discussions on Multiple System Atrophy (MSA) and atypical parkinsonism. MSA Trust UCL Queen Square Institute of Neurology

Analyses of the initial Phase 3 Program of ampreloxetine (Studies 0169 & 0170) will be presented today at 9:40 AM ET in an oral presentation at the Mission MSA International MSA Congress in Boston. Poster sessions: May 9–10. #MSA2025 Program details missionmsa.org/intlmsacongres…

Spring into action this May! Symptomatic nOH affects approximately 70-90% of those with MSA. If you/someone you know diagnosed with MSA experience symptoms of nOH, you may quality to participate in our actively recruiting Phase 3 CYPRESS Study. Learn more: cypress-study.com

Grateful to have attended, participated in, and sponsored the International MSA Congress in Boston, hosted by Mission MSA. Inspiring days full of learning, connection, and commitment to the MSA community. Thank you to all who made it happen! #MSA2025

Today we celebrate #ClinicalTrialsDay! Thank you to the researchers, participants, and caregivers who make clinical progress possible. Your dedication drives innovation and hope. #ClinicalTrialsDay #CTD2025 ACRP - Assoc. of Clinical Research Profession

We are researching an investigational drug aiming to reduce nOH symptoms in MSA patients. Symptoms of nOH can impact the ability to conduct daily activities, especially those requiring standing or walking. Learn more about the Phase 3 CYPRESS study here: cypress-study.com

Theravance Biopharma is currently recruiting for the Phase 3 CYPRESS #clinicaltrial evaluating the efficacy & safety of a once-daily investigational drug with the goal of symptom relief in people with nOH & #multiplesystematrophy. Learn more on qualifying: cypress-study.com